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In strcptozotocin-diabetic rats treated with insulin replacement, liver glycogen is some 35% depleted. Five consecutive daily subcutaneous injections 
with amyiin dose-dependently restored liver glycogen to normal levels. Significant mcreases over insulin-only therapy occurred with amylin doses 
of 10.30 and 100 ,ug/day, representing amylin: insulin ratios of 0.22.0.75 and 2.79. 
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1. INTRODUCTION 
Amylin (11 is a 37 amino-acid hormone co-localized 
and co-secreted from pancreatic &cells along with in- 
sulin. Available data, including isolated perfused pan- 
creas studies [2] and peripheral plasma levels (31 suggest 
that amylin is probably secreted in the range of 525% 
of the rate of insulin. 
Amylin has marked effects on carbohydrate meta- 
bolism in vitro and in vivo. Effects on isolated skeletal 
muscle include inhibition of glucose incorporation into 
glycogen [4], inhibition of glycogen synthase [5], con- 
version of glycogen phosphorylase to the active u-form 
[5,6], reduction of muscle glycogen content [7], and 
stimulation of lactate production [4]. In vivo, amylin 
increases plasma lactate [S], increases endogcnous 
glucose production [9], and increases plasma glucose 
[7,81. 
deficit are unclear. We considered that it could be 
related to amylin deficiency, with a concomitant defi- 
ciency in hepatic glycogen repletion via the ‘indirect’ 
pathway and might be amerliorated by amylin replace- 
ment. In the experiments reported here, we confirmed 
previous filidiIl~s of reduced liver glycogen in ST% rats 
treated with insulin only, and now report that liver 
glycogen was dose-dependently returned to normal 
levels in similar rats additionally treated with sub- 
cutaneous amylin once daily. 
2. MATERIALS AND METHODS 
7. I A nimult 
There wcrc 68 male Harlan-Spl-ague-Da~~tc~ rati (mass 301 :t 3 g) 
in 8 treatment groups. Animals \+ere housed at 22.7 i 0.8”c‘ in a 12: 12 
hour light/dark cvcie (eupcriment\ being performed during the light 
cycle) and Ced and \tatered ad libitum (Diet 1 M-34, Teklnd, 
Rladiwn, %‘I). The rais were sacrificed for harvesitnp of Iivcrx 4 to 5 
houi-\ inro the Ii& cycle. 
The increases in plasma lactate and glucose in the 
fasted rat support the proposition that amylin regulates 
fuel interconversion via the Cori cycle (hepatic glycogen 
+ plasma glucose --t muscle glycogen + plasma lactate 
+ hepatic glycogen [lo]). It has been reported that this 
‘indirect’ pathway is the predominant mechanism of 
hepatic glycogen synthesis in the rat [ll], and it is also 
likely to be a major pathway in man [12]. 
In animal models of type 1 diabetes mellitus, in addi- 
tion to insulin deficiency, there is marked amylin lack 
[2,13-IS]; so too in the human disease [16] (Koda, J. et 
al., 1Inpublished). Thus, type I diabetes is characterized 
by a combined deficiency of insulin and amylin. 
f. STZ diuheric, imtlirr-on!i’ ireutmt’fli (n ~ i/l. Animals \cere in- 
jccted with \treptozotocin (Sigma Chemical Company, St t.ouii, MO: 
Sigma SOl30) di$\ol\ed in \\ater in a do\e or 65 rng:‘kg into the lateral 
t?il vein. Upon exhibiting ‘ 5% glycosuria (Chemstrip uGK, 
Uoehrinler-~lannheinl, Germang), rats \bere commenced upon a 
\liJing+cale dally inrulin treatment regime (Humulin-Ultl-alente, Eli 
Lilly, Indianapolis. IN) aimed towards maintaining aketonuria (b) 
(‘hcrn~rrip) but 5% $ycosuria. Maintaining diabetic rats in thi, 
mctaholic state optimizes survival. Following one week of catablished 
diahcteb, animal\ recci\ed once daily S.C. injection\ of amylin vehicle 
(Icater for injection) for 5 day\ gicrn at the time of the insulin injec- 
tion. 
Rats made diabetic with the g-cell toxin streptozo- 
tocin (STZ) have a marked depletion of liver glycogen 
stores [17-191 that is only partly corrected with insulin 
treatment [19-221. The mechanisms for this residual 
z. 6. 572 &r/h<~r, it~sitlrn + u/?~.~/i~ /~~~~~}~e~~ XXWLX Thcsc 
animal\ were treated identically to those in group 1 except that the 
daily yubcurancou\ injection contained 3 pg (n= 5); IO ~5 (n = 12); 30 
118 (n - 5); 100 pg (n = 5) or 300 IL@ (n = 5) of rat amylin (Bachem lot 
WG185’). The bioacticity of the peptidc used in these experiments 
C~~~~~ri)~r~rlenc,i ockl,crr:A.A. Young, Dept. Physiology, Amylin 
C’orporation, 9373 Townc Centre Drive, San Diego, CA 92121, USA. 
‘Thi\ batch of rat amylin ha\ ~ubsequenrly been found to contain a 
mercury contaminant, belieccd to he interposed between the sulphur 
atom\ of the 2-cyr 7-q-, di,ulphide bridge (personal communication, 
I.eighton and Cobb, Glaxo Inc, Research Triangle Park, NC, USA) 
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\vith insulin alone. Intercstingl!, the highest dose of 
atnylin tested, 300 hg/day, also did not measurably 
restore livet- gl>,cogcn to\xarda nor-tnal, giving an ap- 
parently biphasic dose-response. 
4. DISCUSSION 
The results she\\ that combined replacement of 
atnylin and insulin can t-wore normal le\ els of li\er 
glycogen in ST%-diabetic rats; full restoration is not 
achieved Lvith insulin alone. LVe bclie\e these ohserva- 
tions to be the first demonsrration of a chronic effect of 
atnylin administration. CVe nole that this physiological 
response is caused by a once-daily subcutaneous injec- 
tion in a molar t-atio of amylin to insulin close to that 
thought to occur naturally in healthy animals. 
The mechanisms by \\hich amylin trestores liver 
glycogen in STZ-diabetic trats at-c not determined in the 
present study. However, the observations of the pattern 
of changes in plasma lactate and glucose follo\ving 
atnylin adminislration [8], and of its glycogenolytic ac- 
tion [j-7], caused us to propose that amylin com- 
plements insulin in controlling Cori cycle activity [23]. 
Lactate is a highly intcrconvertable form of metabolic 
carbon; in the rat, it is a preferred substrate for hepatic 
lipogenesis [25] and is the predominant substrate for 
liver glycogenejix [26]. The Cori cycle may constitute an 
important mechanism for the intercon\wsion and 
redistribution of different mcrabolic fuels, and amylin 
may drive one or more parts of this mechanism. In 1931 
such a role \+as proposed for the catecholamines in 
tran5fcrring muscle gl~cogen 10 li\ct- [27]. and a similat 
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role was recently proposed for the redistribution of 
glycogen between muscles following exercise-induced 
depletion [28]. Amylin may share many of the actions 
of catecholamines except that it is present during rest. 
It is notable that, as in the present study, hepatic 
glycogen is also normalized in islet-transplanted STZ 
diabetic rats [29], but not with insulin alone [19-221, 
suggesting the action of an islet factor other than in- 
sulin. Moreover, renal subcapsular islet transplants 
draining into the peripheral circulation were equally ef- 
fective as splenic subcapsular transplants draining into 
the portal circulation; such findings are consistent with 
the concept that the transplanted islets provide a factor 
additional to insulin, which could well be amylin. Since 
the immediate effects of counterregulatory hormones, 
mainly glucagon and catecholamines, are mediated 
largely through hepatic glycogenolysis [30], their effec- 
tiveness is dependent upon the adequacy of liver 
glycogen stores. These stores, in the STZ diabetic rat at 
least, can apparently not be fully maintained by insulin 
alone. The replacement of amylin as well as insulin at 
appropriate doses in type 1 diabetes may be expected to 
promote the ability of the organism to defend itself 
against fuel exhaustion [3 11. 
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The reduced liver glycogen seen in the present study 
with the highest subcutaneous dose of amylin has been 
noted in normal rats treated with 0.75 or 3.0 mg sub- 
cutaneous amylin once daily (personal communication, 
L.A. Campfield, Hoffmann LaRoche, Nutley, NJ); 
this effect could be a consequence of activation of 
hepatic glycogen phosphorylase. 
In summary, insulin-treated and untreated STZ- 
diabetic rats had depleted stores of liver glycogen com- 
pared to non-diabetic controls. When insulin replace- 
ment was supplemented with amylin replacement for 5 
days, liver glycogen stores increased and were not dif- 
ferent from those in non-diabetic controls. These fin- 
dings support the idea that advantages may be expected 
from amylin/insulin co-replacement in type 1 diabetes, 
a disease characterized by a combined deficiency of 
amylin and insulin. 
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